SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences soars on completing acquisition of 19% equity stake in Swiss Parenterals

12 Jun 2024 Evaluate

Eris Lifesciences is currently trading at Rs. 1024.50, up by 18.85 points or 1.87% from its previous closing of Rs. 1005.65 on the BSE.

The scrip opened at Rs. 1002.00 and has touched a high and low of Rs. 1026.60 and Rs. 1002.00 respectively. So far 3407 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1053.90 on 10-Jun-2024 and a 52 week low of Rs. 648.70 on 15-Jun-2023.

Last one week high and low of the scrip stood at Rs. 1053.90 and Rs. 913.65 respectively. The current market cap of the company is Rs. 13894.36 crore.

The promoters holding in the company stood at 54.90%, while Institutions and Non-Institutions held 29.90% and 15.19% respectively.

Eris Lifesciences has completed acquisition of 19% equity stake in Swiss Parenterals (Swiss) from the promoters of the company. Earlier, the company had acquired 51% equity stake in Swiss Parenterals. 

The acquisition of Swiss Parenterals will help company to strengthen India footprint through the launch of a domestic Injectables-focused Branded Formulations business. 

Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.

Eris Lifesciences Share Price

1446.50 -18.90 (-1.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×